CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 enrolled
Drug / intervention
Vildagliptin +1 moredrug
Likely dose
Vildagliptin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02475070
NCT02475070Phase 4Completed
CompareCT.gov

Study of the Effect of Vildagliptin Versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects With Type 2 Diabetes

Lund University·interventional·Posted Jun 18, 2015·Updated May 2, 2019

In Brief

A Phase 4 clinical trial evaluating Vildagliptin and Dapagliflozin for Type 2 Diabetes. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated with effects on glucose homeostasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesSweden
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 18, 2015
Enrollment StartJan 1, 2016
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.0 years ago

Interventions

Vildagliptindrug

Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks

Dapagliflozindrug

Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks